CD28 and neoplasm: These initial findings suggested the possibility that pharmacological activation of co-stimulatory T-cell receptors (for example, CD28, which binds to CD80 and CD86)17 could augment the anti-tumor activity of AMG 330 and, consequently, could provide a rational means of increasing the efficacy of these agents.